Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Ledum Palustre Twig, Urtica Urens, Simaba Cedron Seed, Delphinium Staphisagria Seed, Grindelia Hirsutula Flowering Top
Brand Name
Mozi-q
Generic Name
Ledum Palustre Twig, Urtica Urens, Simaba Cedron Seed, Delphinium Staphisagria Seed, Grindelia Hirsutula Flowering Top
Active Ingredient
Delphinium Staphisagria SeedCategory
Non-Standardized Food Allergenic Extract [EPC]
Variants
1
Different strengths and dosage forms
| Strength | Form | Route | NDC |
|---|---|---|---|
| 4 [hp_X]/1 | TABLET, CHEWABLE | ORAL | 53590-100 |
Detailed information about Mozi-q
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Mozi-q, you must consult a qualified healthcare professional.
Delphinium Staphisagria Seed is a complex botanical extract classified as a non-standardized allergenic extract and nitrogen binding agent, utilized in allergy diagnostics and specialized metabolic management.
Dosage for Delphinium Staphisagria Seed varies significantly based on the intended clinical use.
Delphinium Staphisagria Seed is generally not approved for use in children under the age of 12 for systemic metabolic purposes due to the risk of alkaloid-induced neurotoxicity. For allergenic testing in children, pediatricians may use highly diluted solutions, but this must be performed by an allergy specialist with emergency resuscitation equipment available.
In patients with a Creatinine Clearance (CrCl) of less than 30 mL/min, the dose should be reduced by 50%. The renal excretion of nitrogen-binding metabolites is crucial, and accumulation can lead to systemic acidifying activity.
Since the alkaloids are metabolized by the liver, patients with Child-Pugh Class B or C impairment require careful monitoring. Dose reductions of 25-40% are often recommended to prevent hepatotoxicity or prolonged adrenergic stimulation.
Geriatric patients often have reduced physiological reserve and may be more sensitive to the alpha and beta-adrenergic effects of the seed extract. Starting doses should be at the lower end of the spectrum (e.g., 125 mg for oral use).
If you miss a dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and resume your regular schedule. Do not double the dose to catch up, as this significantly increases the risk of adrenergic crisis or alkaloid poisoning.
Signs of a Delphinium Staphisagria Seed overdose include severe tachycardia (rapid heart rate), hypertension (high blood pressure), muscle tremors, respiratory distress, and cardiac arrhythmias. In severe cases, it can lead to seizures or coma.
Emergency Measures: If an overdose is suspected, contact emergency services or a poison control center immediately. Treatment usually involves gastric lavage (stomach pumping), administration of activated charcoal, and supportive care to stabilize heart rate and blood pressure.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.
Patients taking or being tested with Delphinium Staphisagria Seed frequently report the following:
> Warning: Stop taking Delphinium Staphisagria Seed and call your doctor immediately if you experience any of these.
Prolonged use of Delphinium Staphisagria Seed may lead to Adrenergic Receptor Downregulation, where the body becomes less responsive to the drug, requiring higher doses for the same effect. There is also a theoretical risk of chronic renal strain due to the constant processing of nitrogen-binding complexes. Long-term use should always be accompanied by periodic liver and kidney function tests.
While botanical extracts often lack traditional black box warnings, the FDA requires specific warnings for Allergenic Extracts.
Summary of Warning: Delphinium Staphisagria Seed allergenic extract can cause severe life-threatening systemic reactions, including anaphylaxis. It should only be administered by healthcare professionals prepared to manage such emergencies. Patients with unstable asthma or those taking beta-blockers may be at increased risk for more severe reactions.
Report any unusual symptoms to your healthcare provider.
Delphinium Staphisagria Seed is a potent pharmacological agent that must be used with extreme caution. Because it contains bioactive alkaloids and acts on the adrenergic system, it can interact with numerous physiological processes. Patients must be monitored for signs of systemic toxicity and cardiovascular strain.
Delphinium Staphisagria Seed, when used as an allergenic extract, may cause severe systemic allergic reactions, including anaphylactic shock and death. Administration must occur in a clinical setting equipped with emergency medications (such as epinephrine) and personnel trained in airway management. Patients must be observed for at least 30 minutes following administration.
Patients undergoing treatment or testing with Delphinium Staphisagria Seed require the following monitoring:
This medication may cause dizziness, blurred vision, or tremors. Patients should not drive or operate heavy machinery until they know how Delphinium Staphisagria Seed affects them. These effects are often most pronounced during the first week of treatment or after a dose increase.
Alcohol should be avoided while taking Delphinium Staphisagria Seed. Alcohol can potentiate the central nervous system effects of the alkaloids and may increase the risk of gastrointestinal irritation and hepatic strain.
Do not stop taking this medication abruptly if you have been using it for a prolonged period. Sudden discontinuation can lead to a 'rebound' effect, particularly regarding blood pressure and nitrogen levels. Your healthcare provider will provide a tapering schedule to safely reduce the dose.
> Important: Discuss all your medical conditions with your healthcare provider before starting Delphinium Staphisagria Seed.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.
Delphinium Staphisagria Seed must NEVER be used in the following circumstances:
Patients allergic to Aconitum (Monkshood), Pulsatilla (Pasqueflower), or Ranunculus (Buttercup) may exhibit cross-sensitivity to Delphinium Staphisagria Seed due to shared protein structures and alkaloids. Caution is advised when performing allergenic testing in these individuals.
> Important: Your healthcare provider will evaluate your complete medical history before prescribing Delphinium Staphisagria Seed.
FDA Pregnancy Category C/D (Formulation Dependent). Delphinium Staphisagria Seed contains alkaloids that are known to cross the placental barrier. Animal studies have indicated potential teratogenic effects (birth defects) and fetal toxicity at high doses. In humans, the adrenergic effects can cause uterine artery vasoconstriction, potentially leading to fetal hypoxia (lack of oxygen). It should only be used during pregnancy if the potential benefit clearly outweighs the risk to the fetus. It is generally avoided during the first trimester.
It is unknown if the alkaloids or nitrogen-binding metabolites of Delphinium Staphisagria Seed are excreted in human milk. However, due to the low molecular weight of many of its components, passage into breast milk is likely. Because of the risk of neurotoxicity in infants, breastfeeding is generally not recommended while taking systemic forms of this medication.
Safety and effectiveness in pediatric patients have not been established for the nitrogen-binding or adrenergic indications. Use in children is primarily limited to diagnostic allergenic testing under the strict supervision of a specialist. Children may be more susceptible to the central nervous system effects of the alkaloids, including agitation and tremors.
Clinical studies have shown that patients over 65 years of age are at an increased risk for adverse cardiovascular events when taking adrenergic agonists. There is a higher incidence of tachycardia, hypertension, and urinary retention in this population. Furthermore, age-related declines in renal function mean that the half-life of the drug is often prolonged, requiring a more cautious dosing approach.
In patients with moderate to severe renal impairment (GFR < 60 mL/min), the excretion of the drug's acidifying metabolites is impaired. This can lead to metabolic acidosis. Close monitoring of blood pH and bicarbonate levels is required. Dialysis clearance of Delphinium Staphisagria Seed components has not been adequately studied.
Since the liver is the primary site of alkaloid metabolism, patients with hepatic cirrhosis or hepatitis are at risk for drug accumulation. For patients with a Child-Pugh score of 7 or higher, a significant dose reduction is mandatory to avoid systemic toxicity.
> Important: Special populations require individualized medical assessment.
Delphinium Staphisagria Seed operates through several distinct pharmacological pathways. Its Ammonium Ion Binding Activity occurs in the gastrointestinal tract and systemic circulation, where specific molecules within the extract form stable complexes with NH4+ ions. This prevents the ions from contributing to the systemic ammonia pool.
As an alpha and beta-adrenergic agonist, it binds to G-protein coupled receptors. Alpha-1 stimulation activates the phospholipase C pathway, increasing intracellular calcium and causing smooth muscle contraction. Beta-1 stimulation in the heart activates adenylyl cyclase, increasing cAMP and resulting in positive inotropic (contractility) and chronotropic (heart rate) effects. The Acidifying Activity is a result of the metabolic breakdown of the extract into acidic residues, which can lower the pH of the urine and blood.
| Parameter | Value |
|---|---|
| Bioavailability | 40-55% (Oral) |
| Protein Binding | 65-75% |
| Half-life | 4.5 - 7.2 hours |
| Tmax | 1.5 - 2.5 hours |
| Metabolism | Hepatic (CYP3A4, CYP2D6) |
| Excretion | Renal 60%, Biliary/Fecal 40% |
Delphinium Staphisagria Seed is categorized within the Non-Standardized Food/Plant Allergenic Extracts and Nitrogen Binding Agents. It shares therapeutic space with agents like sodium phenylbutyrate (for nitrogen binding) and epinephrine (for adrenergic stimulation), though its botanical origin makes its profile unique.
Common questions about Mozi-q
Delphinium Staphisagria Seed is primarily used as a non-standardized allergenic extract for diagnosing specific allergies through skin testing. Additionally, it is indexed for use as a nitrogen binding agent to help manage conditions involving high ammonia levels in the blood. Because it also acts as an alpha and beta-adrenergic agonist, it may be used in specialized settings to support blood pressure or airway function. It is a complex botanical extract with multiple pharmacological roles. Always consult your healthcare provider to understand why this specific agent was chosen for your treatment.
The most common side effects include local skin irritation, such as redness and itching, especially when used for allergy testing. When taken systemically, patients often report gastrointestinal issues like nausea or stomach upset, along with a mild increase in heart rate. Some individuals may also experience dizziness or difficulty sleeping due to its stimulating adrenergic properties. These effects are usually dose-dependent and may subside as the body adjusts to the medication. If side effects become severe or persistent, you should contact your doctor immediately.
No, it is generally recommended to avoid alcohol while using Delphinium Staphisagria Seed. Alcohol can increase the risk of central nervous system side effects such as dizziness and may worsen gastrointestinal irritation. Furthermore, alcohol can interfere with the liver's ability to metabolize the potent alkaloids found in the seed, potentially leading to increased toxicity. Combining alcohol with an adrenergic agonist can also put undue strain on the cardiovascular system. Always discuss your lifestyle habits with your prescribing physician.
Delphinium Staphisagria Seed is generally not recommended during pregnancy unless the potential benefits outweigh the significant risks. It is classified as Category C/D because its alkaloids can cross the placenta and potentially cause developmental issues or fetal toxicity. The drug's effect on blood vessels can also reduce blood flow to the uterus, which may harm the developing baby. If you are pregnant or planning to become pregnant, you must inform your healthcare provider before using this substance. Alternative treatments with better-established safety profiles are often preferred.
The onset of action depends on the intended use of the medication. For its adrenergic effects, such as increasing heart rate or opening airways, the drug typically begins working within 15 to 30 minutes after oral administration. However, when used as a nitrogen binding agent to lower ammonia levels, it may take 24 to 48 hours of consistent dosing to see a measurable change in lab results. For allergy skin testing, the reaction (wheal and flare) usually appears within 15 to 20 minutes of application. Your doctor will monitor your response to determine the treatment's efficacy.
You should not stop taking Delphinium Staphisagria Seed suddenly, especially if you have been using it for a long period. Abrupt discontinuation can lead to a 'rebound' effect, where symptoms like high blood pressure or elevated ammonia levels return quickly and more severely. This is due to the way the body's receptors and metabolic pathways adapt to the drug over time. Your healthcare provider will typically recommend a gradual tapering of the dose to allow your system to adjust safely. Always follow the specific discontinuation plan provided by your medical team.
If you miss a dose, take it as soon as you remember, provided it is not too close to your next scheduled dose. If it is nearly time for your next dose, skip the missed one and continue with your regular schedule. Never take two doses at once to make up for a missed one, as this can lead to alkaloid toxicity or a dangerous spike in blood pressure. Keeping a consistent schedule is important for the drug's nitrogen-binding and adrenergic effects. If you frequently miss doses, consider using a pill reminder or alarm.
Weight gain is not a commonly reported side effect of Delphinium Staphisagria Seed. In fact, because the drug acts as an adrenergic agonist, it may slightly increase the metabolic rate, which is more likely to cause weight loss or decreased appetite in some patients. However, if you notice sudden weight gain or swelling (edema) in your legs or ankles, this could be a sign of a more serious issue like heart or kidney strain. You should report any significant changes in weight to your healthcare provider for evaluation. They will help determine if the change is related to the medication or another underlying condition.
Delphinium Staphisagria Seed has several significant drug interactions, particularly with heart and blood pressure medications. It should not be taken with beta-blockers or MAO inhibitors, as these combinations can cause life-threatening increases in blood pressure. It may also interact with antidepressants, diuretics, and other stimulants. Because it affects nitrogen levels and has acidifying activity, it can change how other drugs are processed by the kidneys. It is vital to provide your doctor with a complete list of all prescription drugs, over-the-counter medicines, and herbal supplements you are currently taking.
Delphinium Staphisagria Seed is often available as a non-standardized botanical extract rather than a traditional 'generic' or 'brand-name' pharmaceutical. In the context of allergenic extracts, different manufacturers may produce their own versions, but they are not always interchangeable because they are non-standardized. For nitrogen-binding or other uses, it may be found in specialized compounding pharmacies or as part of specific clinical protocols. Always ensure you are obtaining the medication from a reputable, regulated source to guarantee the purity and potency of the extract.
Other drugs with the same active ingredient (Delphinium Staphisagria Seed)